Faeth Therapeutics, Inc.
FTH · Nasdaq · United States
Share price · FTH
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when FTH's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 12 Nov 2026-20.2%
- 9 Nov 2026-42.5%
- 23 Oct 2026-15.0%
- 10 Aug 2026+17.1%
Nothing announced by FTH that day or the session before.
- 9 Jul 2026+16.1%
Nothing announced by FTH that day or the session before.
- 22 Jun 2026+30.1%
- 12 Jun 2026+20.5%
Nothing announced by FTH that day or the session before.
- 2 Jun 2026-18.7%
- 29 May 2026+20.2%
Nothing announced by FTH that day or the session before.
- 19 May 2026-15.8%
Nothing announced by FTH that day or the session before.
Share of unusual movement by asset
For each asset, the share of FTH's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(4 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | mTORC1/mTORC2 (dual inhibitor)Small molecule | Breast Cancer HR+/HER2- Metastatic Breast Cancer | |
| Phase 2 | PI3K alpha (inhibitor)Small molecule | Breast CancerEndometrial Cancer HR+/HER2- Metastatic Breast Cancer | |
| Phase 1/2 | VISTA (V-domain Ig suppressor of T-cell activation)Monoclonal antibody | Non-Small Cell Lung Cancer | |
| Preclinical / Unstaged | —Small molecule | Colorectal Cancer |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | — | $14M+ $161M short-term inv. | $20M-$13M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | — | $27M+ $160M short-term inv. | $16M-$16M operating cash flow | report ↗ |
| 2026-Q1 | — | — | $152M+ $50M short-term inv. | $170M-$11M operating cash flow | report ↗ |
| 2025-Q3 | — | — | $11M+ $14M short-term inv. | $4.6M-$3.6M operating cash flow | report ↗ |
| 2025-Q2 | — | — | $13M+ $16M short-term inv. | $4.9M-$5.9M operating cash flow | report ↗ |
| 2025-Q1 | — | — | $9.9M+ $24M short-term inv. | $6.9M-$7.1M operating cash flow | report ↗ |
| 2024-Q3 | — | — | $19M+ $28M short-term inv. | $7.3M-$5.5M operating cash flow | report ↗ |
| 2024-Q2 | — | — | $12M+ $40M short-term inv. | $7.1M-$5.8M operating cash flow | report ↗ |
| 2024-Q1 | — | — | $11M+ $47M short-term inv. | $8.0M-$7.6M operating cash flow | report ↗ |
| 2023-Q3 | — | — | $11M+ $61M short-term inv. | $7.1M-$4.7M operating cash flow | report ↗ |
| 2023-Q2 | — | — | $10M+ $69M short-term inv. | $9.4M-$9.5M operating cash flow | report ↗ |
| 2023-Q1 | — | — | $8.1M+ $87M short-term inv. | $10M-$12M operating cash flow | report ↗ |
| 2022-Q3 | — | — | $11M+ $105M short-term inv. | $13M-$6.8M operating cash flow | report ↗ |
| 2022-Q2 | — | — | $9.9M+ $114M short-term inv. | $11M-$12M operating cash flow | report ↗ |
| 2022-Q1 | — | — | $8.7M+ $128M short-term inv. | $12M-$11M operating cash flow | report ↗ |
| 2021-Q3 | — | — | $9.5M+ $147M short-term inv. | $9.7M-$5.6M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | — | $8.7M+ $13M short-term inv. | $5.3M-$20M operating cash flow | report ↗ |
Faeth Therapeutics was acquired by Sensei Biotherapeutics, which reported full-year 2025 results with no revenue disclosed. R&D expenses were $11.0M versus $18.6M YoY, and cash and cash equivalents were $8.67M, while cash, cash equivalents and marketable securities totaled $21.2M, down from $41.3M YoY. Net loss was $21.1M, or $(16.72) per basic and diluted share, versus $30.2M, or $(24.01) per share, YoY, with quarterly net burn of $21.09M.
The Faeth acquisition added PIKTOR, an all-oral combination of serabelisib and sapanisertib targeting the PI3K/AKT/mTOR pathway, as Sensei’s lead program. A concurrent $200M private placement is expected, together with cash on hand, to support topline data from the ongoing Phase 2 endometrial cancer trial (FTH-PIK-201) and initiation of the planned Phase 1b HR+/HER2- advanced breast cancer trial (FTH-PIK-101), both expected by year-end 2026, with additional potential opportunities in ovarian and lung cancer. Sensei is also completing a Phase 1/2 trial of solnerstotug in advanced solid tumors.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | — | — | $10.0M+ $31M short-term inv. | $7.5M-$25M operating cash flow | report ↗ |
| 2023-FY | — | — | $13M+ $53M short-term inv. | $8.5M-$32M operating cash flow | report ↗ |
| 2022-FY | — | — | $18M+ $89M short-term inv. | $12M-$39M operating cash flow | report ↗ |
| 2021-FY | — | — | $7.2M+ $140M short-term inv. | $9.2M-$30M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 49 purchases ($2.5M), 45 sales ($2.3M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-10-30 | Parikh Anand Kiran · director, President and CEO | Gift | 100,000 | — | — | Form 4 |
| 2026-10-30 | Parikh Anand Kiran · director, President and CEO | Gift | 100,000 | — | — | Form 4 |
| 2026-10-23 | Schayowitz Adam · director | Award / grant (derivative) | 25,000 | — | — | Form 4 |
| 2026-09-11 | Vousden Karen H · director | Award / grant (derivative) | 25,000 | — | — | Form 4 |
| 2026-07-21 | Parikh Anand Kiran · director, President and CEO | Award / grant (derivative) | 398,018 | — | — | Form 4 |
| 2026-07-21 | Craver Josiah · PAO | Award / grant (derivative) | 30,824 | — | — | Form 4 |
| 2026-07-01 | STEPHENSON BRIAN C · Chief Financial Officer | Open-market purchase | 4,400 | $23.40 | $103K | Form 4 |
| 2026-07-01 | STEPHENSON BRIAN C · Chief Financial Officer | Open-market purchase | 600 | $24.22 | $15K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 30 reporting institutions held 2.3M shares ($70.3M, 8.9% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | Vivo Capital, LLC | 722,020 | $22.8M |
| 2 | Cormorant Asset Management, LP | 306,222 | $9.7M |
| 3 | STEMPOINT CAPITAL LP | 265,746 | $8.4M |
| 4 | MILLENNIUM MANAGEMENT LLC | 146,565 | $4.6M |
| 5 | FRANKLIN RESOURCES INC | 133,506 | $4.2M |
| 6 | Caligan Partners LP | 126,002 | $4.0M |
| 7 | Trails Edge Capital Partners, LP | 125,000 | $3.9M |
| 8 | MARSHALL WACE, LLP | 65,730 | $2.1M |
| 9 | GOLDMAN SACHS GROUP INC | 61,568 | $1.9M |
| 10 | SUVRETTA CAPITAL MANAGEMENT, LLC | 34,549 | $1.1M |
| 11 | BANK OF AMERICA CORP /DE/ | 33,025 | $1.0M |
| 12 | RENAISSANCE TECHNOLOGIES LLC | 32,041 | $1.0M |
| 13 | Logos Global Management LP | 30,000 | $946K |
| 14 | BOOTHBAY FUND MANAGEMENT, LLC | 26,124 | $823K |
| 15 | Brevan Howard Capital Management LP | 20,333 | $641K |